Last reviewed · How we verify
NCT06631378
Transverse Versus Longitudinal Groin Incision in Vascular Surgery
NA trial testing Transverse groin incision in Peripheral Arterial Disease(PAD) in 232 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Kolding Sygehus |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 232 |
| Start date | 1 March 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 July 2027 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Transverse groin incision
- Longitudinal incision
Conditions studied
- Peripheral Arterial Disease(PAD) — all drugs for Peripheral Arterial Disease(PAD) →
- Aneurysmal Disease — all drugs for Aneurysmal Disease →
Sponsor
Kolding Sygehus — full company profile →
Who can join
Eligibility, any sex, with Peripheral Arterial Disease(PAD) or Aneurysmal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to examine whether incision type has an influence on the development of groin wound complications after operation in the groin in vascular surgery. The main questions it aims to answer are: Does a transverse incision in the groin lead to fewer surgical site complications than a longitudinal incision? Does a transverse incision lead to fewer readmissions, fewer reoperations, shorter length of hospital stay, and a lower amputation rate. Participants will undergo vascular surgery in the groin with either a transverse or longitudinal incision. The incision type will be selected randomly.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06631378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Arterial Disease(PAD)
Currently open trials in the same condition.
- NCT07016698 — Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry) · NA · recruiting
- NCT07157475 — Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors · recruiting
- NCT06758921 — Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Per · recruiting
- NCT07048925 — Iliac Stent-Grafts in TASC C-D Lesions · active not recruiting
- NCT02748226 — Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery · recruiting
Other Kolding Sygehus trials
Trials by the same sponsor.
- NCT06642402 — Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles · recruiting
- NCT06373913 — The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom · recruiting
- NCT04574336 — Scandinavian Humeral Diaphyseal Fracture Trial · NA · recruiting
- NCT04734795 — The Prevalence of Dysfunctional Breathing in Children and Adolescents With Asthma · completed
- NCT04424186 — 'Rehabilitation for Life' · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06631378 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kolding Sygehus
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06631378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing